Where Is the Cap Oligosaccharide?

Leishmania parasites are covered by a complicated glycocalyx, which is a pivotal factor in promoting virulence. One of the most abundant glycolipids based on the Leishmania promastigote surface is lipophosphoglycan (LPG), which is composed of four domains: terminating cap oligosaccharide, linear phosphoglycan chain (PG), polypeptide sugar core, and GPI anchor. The external cap oligosaccharide at the distal end of LPG has various glycosyl compositions, which are linked together through phosphate bonds to form a cap-like structure. LPG has been proven to activate T cells and promote Th1 responses, thereby mediating protection against intracellular stages of Leishmania and serving as an attractive vaccine target.

Fig.1 Structure of the Leishmania LPG. (Forestier, et al., 2015)

Leishmania Parasites Cap Oligosaccharide Production Services at CD BioGlyco

• Customized synthesis services
  CD BioGlyco provides customized Leishmania parasites cap oligosaccharide synthesis services based on research needs, including steps such as designing and synthesizing a specific core structure, connecting glycosyl units, and purification.
• Modification and synthesis services
  CD BioGlyco offers various modification methods for the synthesis of Leishmania cap oligosaccharide, which changes its structure, functions, or biological activity. The following are the modification synthesis methods provided.
  • Glycosyl modification
    Introduce different glycosyl units: We use chemical synthesis methods or enzyme-catalyzed reactions to introduce different glycosyl units into the core structure. For example, glucose, galactose, or mannose.
    Adjust the connection mode of glycosyl units: We change the connection mode of glycosyl units in cap oligosaccharides, such as changing the connection position, connection sequence, or the stereochemical configuration of the connected glycosidic bonds.
  • Chemical modification
    CD BioGlyco uses chemical reactions (such as substitution, esterification, and amination) to introduce different functional groups on the sugar groups of cap oligosaccharides, which may change the physicochemical properties, stability, and interaction properties of cap oligosaccharides.
• Structure confirmation and analysis services
  CD BioGlyco uses nuclear magnetic resonance (NMR), mass spectrometry, and other structural analysis techniques to conduct structure verification and purity analysis of the synthesized Leishmania cap oligosaccharide.
• Immunity assessment services
  CD BioGlyco provides immune assessment for cap oligosaccharides. We apply the synthesized cap oligosaccharide to animal models or in vitro experiments to evaluate its protective ability and immune efficacy against Leishmania infection, providing an essential reference for vaccine research.
• Vaccine development services
  CD BioGlyco has a specialized Glyco™ Vaccine Development Platform. We use cap oligosaccharides as antigens or auxiliary ligands, combined with appropriate immune adjuvants, delivery systems, or carrier designs, to develop new vaccine candidates to improve immune and protective effects.

Fig.2 Leishmania parasites cap oligosaccharide production services. (CD BioGlyco)

Applications

• Vaccine research: Cap oligosaccharide is an important antigen that is applied to support the research of vaccine candidates and the evaluation of vaccine immune efficacy.
• Drug development: The production of Leishmania cap oligosaccharides is used for efficacy evaluation, target identification, and drug design in drug development.
• Research on pathogenic mechanism: The production of cap oligosaccharides may support in-depth research into the pathogenic mechanisms of Leishmania parasites.
• Diagnostic method development: Cap oligosaccharides play a vital role in Leishmania infection, and are used as targets or markers for diagnostic methods. The cap oligosaccharides produced support the development and evaluation of novel diagnostic methods.

Advantages

• Our scientists have an in-depth understanding of the structure and synthesis pathway of cap oligosaccharides from the Leishmania parasite and perform accurate and efficient structural analysis and synthesis.
• CD BioGlyco designs and synthesizes customized cap oligosaccharide structures based on specific research or application needs.
• CD BioGlyco provides reliable cap oligosaccharide products with fast and timely delivery.

CD BioGlyco has the world's leading oligosaccharide production technology, which provides professional Leishmania parasite cap oligosaccharide production and vaccine development services. Please feel free to contact us if you would like to inquire about the specific details of production.

References

1. Osanya, A.; et al. Pathogen-derived oligosaccharides improve innate immune response to intracellular parasite infection. The American Journal of Pathology. 2011, 179(3): 1329-1337.
2. Forestier, C.L.; et al. Leishmania lipophosphoglycan: how to establish structure-activity relationships for this highly complex and multifunctional glycoconjugate? Frontiers in Cellular and Infection Microbiology. 2015, 4, 193.